Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors

摘要: The epidermal growth factor receptor (EGFR) family members are potential targets for therapy using extra-cellular domain binding agents, such as the antibodies trastuzumab and cetuximab, or labeled with therapeutically useful radionuclides toxins. This is especially case when tumor cells resistant to chemotherapy tyrosine kinase inhibitors. Studies concerning expression of these receptors in prostate cancer vary literature, possibly due differences patient inclusion, sample preparations scoring criteria. In our study, EGFR, HER2 HER3 was analyzed samples from primary tumors corresponding lymph node metastases 12 patients. EGFR scored immunohistochemical HercepTest criteria (0, 1+, 2+ 3+), while no, weak strong staining. There were 5 EGFR-positive (2+ 3+) 6 metastases, there upregulation one metastasis. Only 4 patients had marked their downregulation cases metastases. Thus, a total 8 out HER2-positive. Of tumors, 9 expressed only 2 recognizable staining, so 7 appeared have downregulated expression. positive co-expression HER2, this observed tendencies increased comparison tumors. results encouraging studies involving more Possible strategies EGFR- HER2-targeted briefly discussed present regard